CR20220631A - Compuestos de dihidroquinolinsulfonamida de ciclobutilo - Google Patents

Compuestos de dihidroquinolinsulfonamida de ciclobutilo

Info

Publication number: CR20220631A
Authority: CR; Costa Rica
Prior art keywords: compounds; dihydroquinoline; cyclobutyl; sulfonamide compounds; formula
Prior art date: 2020-06-10

Application number

CR20220631A

Other languages

English (en)

Spanish (es)

Inventor

Benjamin C Milgram

Haoxuan Wang

Isaac E Marx

Alan H Cherney

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-06-10

Filing date

2021-06-10

Publication date

2023-01-23

2021-06-10 Application filed by Amgen Inc filed Critical Amgen Inc

2023-01-23 Publication of CR20220631A publication Critical patent/CR20220631A/es

Links

PAPIDPZGJVSNRS-UHFFFAOYSA-N N-cyclobutyl-1,2-dihydroquinoline-2-sulfonamide Chemical class O=S(C1NC2=CC=CC=C2C=C1)(NC1CCC1)=O PAPIDPZGJVSNRS-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
206010011224 Cough Diseases 0.000 abstract 1
101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 abstract 1
208000003251 Pruritus Diseases 0.000 abstract 1
108010052164 Sodium Channels Proteins 0.000 abstract 1
102000018674 Sodium Channels Human genes 0.000 abstract 1
102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 abstract 1
208000027520 Somatoform disease Diseases 0.000 abstract 1
108010053752 Voltage-Gated Sodium Channels Proteins 0.000 abstract 1
102000016913 Voltage-Gated Sodium Channels Human genes 0.000 abstract 1
-1 cyclobutyl dihydroquinoline sulfonamide compound Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
208000027753 pain disease Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pain & Pain Management (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)

CR20220631A 2020-06-10 2021-06-10 Compuestos de dihidroquinolinsulfonamida de ciclobutilo CR20220631A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US202063037001P	2020-06-10	2020-06-10
PCT/US2021/036896 WO2021252820A1 (fr)	2020-06-10	2021-06-10	Composés de cyclobutyle dihydroquinoléine sulfonamide

Publications (1)

Publication Number	Publication Date
CR20220631A true CR20220631A (es)	2023-01-23

Family

ID=76797115

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR20220631A CR20220631A (es)	2020-06-10	2021-06-10	Compuestos de dihidroquinolinsulfonamida de ciclobutilo

Country Status (31)

Country	Link
US (3)	US12240839B2 (fr)
EP (2)	EP4653050A3 (fr)
JP (2)	JP7739051B2 (fr)
KR (1)	KR20230022996A (fr)
CN (2)	CN115697971B (fr)
AR (1)	AR122592A1 (fr)
AU (1)	AU2021288696B2 (fr)
BR (1)	BR112022025201A2 (fr)
CA (1)	CA3183889A1 (fr)
CL (1)	CL2022003499A1 (fr)
CO (1)	CO2022017903A2 (fr)
CR (1)	CR20220631A (fr)
DK (1)	DK4165024T3 (fr)
ES (1)	ES3037072T3 (fr)
FI (1)	FI4165024T3 (fr)
HR (1)	HRP20251229T1 (fr)
HU (1)	HUE072945T2 (fr)
IL (2)	IL326793A (fr)
JO (1)	JOP20220334A1 (fr)
LT (1)	LT4165024T (fr)
MA (1)	MA59968B1 (fr)
MX (2)	MX2022015856A (fr)
PE (1)	PE20230860A1 (fr)
PL (1)	PL4165024T3 (fr)
PT (1)	PT4165024T (fr)
RS (1)	RS67268B1 (fr)
SI (1)	SI4165024T1 (fr)
SM (1)	SMT202500328T1 (fr)
TW (1)	TWI899251B (fr)
UY (1)	UY39263A (fr)
WO (1)	WO2021252820A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP7880201B2 (ja) *	2020-06-10	2026-06-25	アムジエン・インコーポレーテツド	シクロプロピルジヒドロキノリンスルホンアミド化合物
JP7739051B2 (ja)	2020-06-10	2025-09-16	アムジエン・インコーポレーテツド	シクロブチルジヒドロキノリンスルホンアミド化合物
CN117794918A (zh)	2021-06-04	2024-03-29	沃泰克斯药物股份有限公司	经取代的四氢呋喃类似物作为钠通道调节剂
SMT202600064T1 (it)	2021-06-04	2026-03-09	Vertex Pharma	Forme farmaceutiche solide e regimi di dosaggio comprendenti (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-metossi-fenil)-4,5-dimetil-5-(trifluorometil) tetraidrofuran-2-carbonil]ammino]piridin-2-carbossammide
WO2022256842A1 (fr)	2021-06-04	2022-12-08	Vertex Pharmaceuticals Incorporated	Tétrahydrofuranes à substitution hydroxy et (halo)alkoxy utiles en tant que modulateurs de canaux sodiques
SI4347031T1 (sl)	2021-06-04	2026-01-30	Vertex Pharmaceuticals Incorporated	N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
US20240368135A1 (en)	2021-06-04	2024-11-07	Vertex Pharmaceuticals Incorporated	Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
CA3221939A1 (fr)	2021-06-04	2022-12-08	Vertex Pharmaceuticals Incorporated	Analogues de n-(hydroxyalkyl(hetero)aryl)tetrahydrofurane carboxamide en tant que modulateurs de canaux sodiques
EP4385978A4 (fr) *	2021-08-12	2025-08-13	Tyk Medicines Inc	Composé polycyclique et son utilisation
AU2023255558A1 (en)	2022-04-22	2024-10-31	Vertex Pharmaceuticals Incorporated	Heteroaryl compounds for the treatment of pain
AU2023257313A1 (en)	2022-04-22	2024-10-31	Vertex Pharmaceuticals Incorporated	Heteroaryl compounds for the treatment of pain
IL316422A (en)	2022-04-22	2024-12-01	Vertex Pharma	Heteroaryl compounds for pain treatment
JP2025513455A (ja)	2022-04-22	2025-04-24	バーテックスファーマシューティカルズインコーポレイテッド	疼痛の治療のためのヘテロアリール化合物
KR20250120351A (ko)	2022-12-06	2025-08-08	버텍스 파마슈티칼스 인코포레이티드	나트륨 채널의 치환된 테트라하이드로푸란 조절제의 합성을 위한 방법
TW202535867A (zh)	2023-10-23	2025-09-16	美商維泰克斯製藥公司	用於治療疼痛之鈉通道調節劑及其固體形式的製備方法
KR20260116140A (ko)	2023-10-23	2026-07-28	버텍스 파마슈티칼스 인코포레이티드	통증 치료를 위한 헤테로아릴 화합물
KR20260116141A (ko)	2023-10-23	2026-07-28	버텍스 파마슈티칼스 인코포레이티드	통증 치료용 화합물 및 이의 고체 형태의 제조방법
KR20260118418A (ko)	2023-10-23	2026-07-30	버텍스 파마슈티칼스 인코포레이티드	통증 치료를 위한 헤테로아릴 화합물
AU2024393245A1 (en)	2023-12-07	2026-06-18	Vertex Pharmaceuticals Incorporated	Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain
TW202606663A (zh)	2024-06-28	2026-02-16	美商維泰克斯製藥公司	用於治療疼痛之雜芳基化合物
LU605402B1 (en)	2024-07-11	2026-07-14	Sea4Us Biotecnologia E Recursos Marinhos Sa	Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026030525A1 (fr)	2024-07-31	2026-02-05	Vertex Pharmaceuticals Incorporated	Formes galéniques et schémas posologiques de zilvétrigine pour le traitement de la douleur

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4412994A (en)	1980-04-24	1983-11-01	Interx Research Corporation	Mannich-base hydroxamic acid prodrugs, compositions and use
PT72878B (en)	1980-04-24	1983-03-29	Merck & Co Inc	Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US5707985A (en)	1995-06-07	1998-01-13	Tanabe Seiyaku Co. Ltd.	Naphthyl-, quinolyl- and isoquinolyl- sulfonamide derivatives as cell adhesion modulators
PA8444901A1 (es)	1997-01-28	2000-05-24	Hoffmann La Roche	Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios
US6858621B2 (en)	2002-04-26	2005-02-22	Ortho-Mcneil Pharmaceutical, Inc.	2-(quinolonyl)-fused heterocycles as androgen receptor modulators
CA2511089A1 (fr)	2003-01-17	2004-08-05	Warner-Lambert Company Llc	Antagonistes du recepteur des androgenes
US7009052B2 (en)	2003-03-20	2006-03-07	Warner Lambert Company Llc	Sulfonamide derivatives
WO2006117762A2 (fr)	2005-05-03	2006-11-09	Ranbaxy Laboratories Limited	Agents antimicrobiens
CN101218235A (zh)	2005-05-10	2008-07-09	沃泰克斯药物股份有限公司	作为离子通道调控剂的二环衍生物
EP1888558B1 (fr)	2005-05-16	2011-10-05	Vertex Pharmaceuticals, Inc.	Derives bicycliques en tant que modulateurs de canaux ioniques
GT200600381A (es)	2005-08-25	2007-03-28		Compuestos organicos
TWI385161B (zh)	2006-02-02	2013-02-11	Mitsubishi Tanabe Pharma Corp	含氮雜雙環化合物
WO2010045197A1 (fr)	2008-10-17	2010-04-22	Xenon Pharmaceuticals, Inc.	Composés spiro-oxindole et leur utilisation comme agents thérapeutiques
GB0907551D0 (en)	2009-05-01	2009-06-10	Univ Dundee	Treatment or prophylaxis of proliferative conditions
CN102471235A (zh)	2009-07-11	2012-05-23	拜耳医药股份有限公司	利用环烷基的放射性标记方法
CN102030780B (zh) *	2010-10-26	2014-01-29	浙江大学	一种手性螺环磷酸和制备方法及其应用
AU2012296529A1 (en)	2011-08-17	2014-02-20	Amgen Inc.	Heteroaryl sodium channel inhibitors
WO2013086229A1 (fr)	2011-12-07	2013-06-13	Amgen Inc.	Inhibiteurs aryle et hétéroaryle bicycliques des canaux calciques
WO2013122897A1 (fr)	2012-02-13	2013-08-22	Amgen Inc.	Inhibiteurs des canaux sodiques de type dihydrobenzoxazine et tétrahydroquinoxaline
US9051311B2 (en)	2012-03-09	2015-06-09	Amgen Inc.	Sulfamide sodium channel inhibitors
US9212182B2 (en)	2013-06-12	2015-12-15	Amgen Inc.	Bicyclic sulfonamide compounds as sodium channel inhibitors
CN107406380B (zh) *	2015-02-04	2020-04-28	上海海雁医药科技有限公司	杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途
AU2016226340B2 (en)	2015-03-02	2019-11-07	Amgen Inc.	Bicyclic ketone sulfonamide compounds
MY197595A (en)	2015-12-18	2023-06-27	Amgen Inc	Alkyl dihydroquinoline sulfonamide compounds
WO2017106872A1 (fr)	2015-12-18	2017-06-22	Amgen Inc	Composés sulfonamides de dihydroquinoline d'alcynyle
JP2019512519A (ja)	2016-03-21	2019-05-16	ザスクリプスリサーチインスティテュート	Ｐｄ（ＩＩ）触媒エナンチオ選択的β−メチレンＣ（ｓｐ３）−Ｈ結合活性化
JP7739051B2 (ja)	2020-06-10	2025-09-16	アムジエン・インコーポレーテツド	シクロブチルジヒドロキノリンスルホンアミド化合物
JP7880201B2 (ja) *	2020-06-10	2026-06-25	アムジエン・インコーポレーテツド	シクロプロピルジヒドロキノリンスルホンアミド化合物
EP4385978A4 (fr)	2021-08-12	2025-08-13	Tyk Medicines Inc	Composé polycyclique et son utilisation
JP2024529736A (ja)	2021-08-19	2024-08-08	アムジエン・インコーポレーテツド	トランスハロシクロブタンの立体選択的調製

2021
- 2021-05-31 JP JP2021090960A patent/JP7739051B2/ja active Active
- 2021-06-10 DK DK21737878.5T patent/DK4165024T3/da active
- 2021-06-10 CN CN202180040963.2A patent/CN115697971B/zh active Active
- 2021-06-10 ES ES21737878T patent/ES3037072T3/es active Active
- 2021-06-10 EP EP25188659.4A patent/EP4653050A3/fr active Pending
- 2021-06-10 TW TW110121155A patent/TWI899251B/zh active
- 2021-06-10 MX MX2022015856A patent/MX2022015856A/es unknown
- 2021-06-10 JO JOP/2022/0334A patent/JOP20220334A1/ar unknown
- 2021-06-10 HR HRP20251229TT patent/HRP20251229T1/hr unknown
- 2021-06-10 IL IL326793A patent/IL326793A/en unknown
- 2021-06-10 WO PCT/US2021/036896 patent/WO2021252820A1/fr not_active Ceased
- 2021-06-10 MA MA59968A patent/MA59968B1/fr unknown
- 2021-06-10 SI SI202130354T patent/SI4165024T1/sl unknown
- 2021-06-10 SM SM20250328T patent/SMT202500328T1/it unknown
- 2021-06-10 RS RS20250992A patent/RS67268B1/sr unknown
- 2021-06-10 US US17/633,151 patent/US12240839B2/en active Active
- 2021-06-10 PE PE2022002892A patent/PE20230860A1/es unknown
- 2021-06-10 BR BR112022025201A patent/BR112022025201A2/pt unknown
- 2021-06-10 FI FIEP21737878.5T patent/FI4165024T3/fi active
- 2021-06-10 KR KR1020237000972A patent/KR20230022996A/ko active Pending
- 2021-06-10 UY UY0001039263A patent/UY39263A/es unknown
- 2021-06-10 CR CR20220631A patent/CR20220631A/es unknown
- 2021-06-10 CN CN202510007130.6A patent/CN119735588A/zh active Pending
- 2021-06-10 PT PT217378785T patent/PT4165024T/pt unknown
- 2021-06-10 AU AU2021288696A patent/AU2021288696B2/en active Active
- 2021-06-10 LT LTEPPCT/US2021/036896T patent/LT4165024T/lt unknown
- 2021-06-10 CA CA3183889A patent/CA3183889A1/fr active Pending
- 2021-06-10 AR ARP210101586A patent/AR122592A1/es unknown
- 2021-06-10 PL PL21737878.5T patent/PL4165024T3/pl unknown
- 2021-06-10 HU HUE21737878A patent/HUE072945T2/hu unknown
- 2021-06-10 EP EP21737878.5A patent/EP4165024B1/fr active Active
- 2021-06-11 US US17/344,947 patent/US20210387978A1/en not_active Abandoned
2022
- 2022-11-17 IL IL298325A patent/IL298325B2/en unknown
- 2022-12-09 MX MX2025010506A patent/MX2025010506A/es unknown
- 2022-12-09 CL CL2022003499A patent/CL2022003499A1/es unknown
- 2022-12-09 CO CONC2022/0017903A patent/CO2022017903A2/es unknown
2025
- 2025-01-28 US US19/039,379 patent/US20250171425A1/en active Pending
- 2025-09-02 JP JP2025145171A patent/JP2025179137A/ja active Pending

Also Published As

Publication number	Publication date
CO2022017903A2 (es)	2022-12-20
DK4165024T3 (da)	2025-09-08
JOP20220334A1 (ar)	2023-01-30
EP4165024B1 (fr)	2025-07-16
JP2021195368A (ja)	2021-12-27
SMT202500328T1 (it)	2025-11-10
SI4165024T1 (sl)	2025-12-31
TWI899251B (zh)	2025-10-01
IL298325B1 (en)	2026-04-01
JP2025179137A (ja)	2025-12-09
BR112022025201A2 (pt)	2023-02-28
JP7739051B2 (ja)	2025-09-16
WO2021252820A1 (fr)	2021-12-16
AU2021288696A1 (en)	2022-12-15
AR122592A1 (es)	2022-09-21
FI4165024T3 (fi)	2025-08-29
EP4653050A2 (fr)	2025-11-26
IL326793A (en)	2026-04-01
RS67268B1 (sr)	2025-10-31
HRP20251229T1 (hr)	2025-12-19
AU2021288696B2 (en)	2026-06-04
US12240839B2 (en)	2025-03-04
US20210387978A1 (en)	2021-12-16
CN119735588A (zh)	2025-04-01
CN115697971A (zh)	2023-02-03
CA3183889A1 (fr)	2021-12-16
PE20230860A1 (es)	2023-05-30
PL4165024T3 (pl)	2025-12-08
IL298325B2 (en)	2026-08-01
HUE072945T2 (hu)	2025-12-28
US20220306604A1 (en)	2022-09-29
KR20230022996A (ko)	2023-02-16
ES3037072T3 (en)	2025-09-26
MX2025010506A (es)	2025-10-01
UY39263A (es)	2021-11-30
LT4165024T (lt)	2025-11-10
EP4165024A1 (fr)	2023-04-19
MX2022015856A (es)	2023-01-24
CL2022003499A1 (es)	2023-08-04
IL298325A (en)	2023-01-01
MA59968B1 (fr)	2025-10-31
US20250171425A1 (en)	2025-05-29
PT4165024T (pt)	2025-10-23
CN115697971B (zh)	2025-01-28
EP4653050A3 (fr)	2026-04-15
TW202214586A (zh)	2022-04-16

Publication	Publication Date	Title
MX2025010506A (es)	2025-10-01	Compuestos de dihidroquinolinsulfonamida de ciclobutilo
MX2022015622A (es)	2023-01-11	Compuestos de dihidroquinolin sulfonamida de ciclopropilo.
EP4595965A3 (fr)	2025-08-13	Composés hétéroalkyl dihydroquinoline sulfonamides
GEP20257750B (en)	2025-03-25	2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
UA86614C2 (ru)	2009-05-12	Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
MX2023001445A (es)	2023-05-08	Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4.
MXPA04005156A (es)	2004-08-11	Antagonistas del receptor de adenosina a2a.
MX2024003738A (es)	2024-06-19	Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromatico.
MX2022015554A (es)	2023-01-30	Moduladores de molecula peque?a de interleucina 17 (il-17).
MX2024003459A (es)	2024-04-23	Metodos de tratamiento de trastornos metabolicos.
MX2024014315A (es)	2024-12-06	Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
GEAP202516737A (en)	2025-06-10	Compounds for treating cancer
MX2025000635A (es)	2025-04-02	Compuestos cíclicos y métodos de utilización de estos
ZA202309001B (en)	2025-03-26	Abhd6 antagonist
MX2023012039A (es)	2024-03-05	Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos.
MX2021003508A (es)	2021-05-27	Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
GEAP202516820A (en)	2025-09-10	Prmt5-mta inhibitor
MX2019014321A (es)	2020-02-05	Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
MX2024003930A (es)	2024-06-28	Moduladores de trpml, sus composiciones y metodos de uso.
MX2025001111A (es)	2025-04-02	Nuevas sulfonamidas y su uso como agentes neuroprotectores y/o neurorrestauradores
MX2022008930A (es)	2022-10-18	Composiciones farmaceuticas y sus usos.
AU2002254124A1 (en)	2002-09-12	Aryl-n-cyanoguanidines and methods related thereto
WO2024168106A3 (fr)	2024-10-10	Modulateurs de trpml, leurs compositions et procédés d'utilisation
MX2024013549A (es)	2025-02-10	Heterociclos novedosos, métodos de preparación y usos de los mismos
WO2024050431A3 (fr)	2024-05-02	Tapinarof et ses analogues destinés à être utilisés dans le traitement de maladies médiées par ahr